Business

University of Pittsburgh, UPMC play role in Moderna Covid-19 vaccine trials

By Paul J. Gough – Reporter, Pittsburgh Business Times

Moderna’s coronavirus vaccine may be game-changer in COVID-19 fight Moderna is now the second pharmaceutical company to announce its vaccine is more than 90% effective, according to early results.

By Paul J. Gough – Reporter, Pittsburgh Business Times

PITTSBURGH — When Moderna’s Covid-19 vaccine gets to the point where it’s being administered, Pittsburgh will once again have played a role in helping to ease a global health crisis.

That’s because the University of Pittsburgh and UPMC’s Pittsburgh Vaccine Clinical Trials Unit at UPMC Children’s Hospital of Pittsburgh have been a clinical trial site for the Moderna and two other Covid-19 vaccines that are in earlier stages of development. About 250 people from the Pittsburgh region have either gotten the two-shot Moderna vaccine or placebos as part of the Phase III clinical trial.

Moderna on Monday provided an interim analysis of its Phase III trial that showed a vaccine efficacy rate of 94.5% among more than 30,000 people who participated in the study in the U.S. That, along with an early 90% effectiveness rate reported last week for the Pfizer Inc. study, buoyed hopes that the vaccines would be a significant weapon in the global fight against Covid-19.

Read more from our news partners at the Pittsburgh Business Times.

TRENDING NOW:

  • Stimulus check update: What are the chances for a second $1,200 check?
  • Nursing home resident shares concerns as Pa. state inspection reports are released
  • Some changes could be coming as COVID-19 cases jump to record highs in Allegheny County
  • VIDEO: Can your employer require you to get a COVID-19 vaccine once it’s available?
  • DOWNLOAD the Channel 11 News app for breaking news alerts

    • Cooperation with Pa. COVID-19 contact tracers plummeting


    Pittsburgh Business Times

    Most Read